Advancing a vaccine targeting genetic amyotrophic lateral sclerosis (C9orf72 ALS) to the clinical stage

Project Information

GA-VAX

Grant agreement ID: 101057649

DOI

10.3030/101057649

EC signature date 22 March 2022

Start date 1 June 2022

End date 31 March 2026

Funded under

• The European Innovation Council (EIC)

Total cost

€ 2 499 810,00

EU contribution

€ 2 499 810,00

Coordinated by

DEUTSCHES ZENTRUM FUR NEURODEGENERATIVE ERKRANKUNGEN EV
Germany

CORDIS provides links to public deliverables and publications of HORIZON projects.

Links to deliverables and publications from FP7 projects, as well as links to some specific result types such as dataset and software, are dynamically retrieved from OpenAIRE .

Deliverables

Documents, reports (1)

Website and Project Logo

Setting up a website and project logon inlcudng information on social media links.

Publications

Peer reviewed articles (1)

Development and Preclinical Evaluation of a Copper-64-Labeled Antibody Targeting Glycine-Alanine Dipeptides for PET Imaging of C9orf72-Associated Amyotrophic Lateral Sclerosis/Frontotemporal Dementia

Author(s): Monireh Shojaei; Qihui Zhou; Giovanna Palumbo; Rebecca Schaefer; Janne Kaskinoro; Pirjo Vehmaan-Kreula; Peter Bartenstein; Matthias Brendel; Dieter Edbauer; Simon Lindner
Published in: ACS Pharmacology & Translational Science, 2024, ISSN 2575-9108
Publisher: American Chemical Society
DOI: 10.1021/acsptsci.4c00037